Rhythm Pharmaceuticals (RYTM) Finished Goods (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has 5 years of Finished Goods data on file, last reported at $14.5 million in Q3 2025.

• On a quarterly basis, Finished Goods rose 80.97% year-over-year to $14.5 million in Q3 2025; TTM through Sep 2025 was $14.5 million, a 80.97% increase from a year earlier, with the FY2024 full-year figure at $10.7 million, up 270.12% from the prior year.
• Finished Goods for Q3 2025 stood at $14.5 million, up from $13.6 million in the prior quarter.
• Over the last five years, Finished Goods for RYTM reached as high as $14.5 million in Q3 2025 and fell as low as $111000.0 in Q4 2021.
• Historically, Finished Goods has averaged $5.7 million across 5 years, with a median of $2.9 million in 2023.
• Across the five-year window, Finished Goods jumped 75.68% in 2022 and jumped 1384.62% in 2023, its largest moves.
• Year by year, Finished Goods stood at $111000.0 in 2021, then soared by 75.68% to $195000.0 in 2022, then soared by 1384.62% to $2.9 million in 2023, then surged by 270.12% to $10.7 million in 2024, then jumped by 35.71% to $14.5 million in 2025.
• Per Business Quant data, the three most recent Finished Goods figures were $14.5 million in Q3 2025, $13.6 million in Q2 2025, and $12.6 million in Q1 2025.